Brief Description
The AUTUMN Study is for adults living with primary membranous nephropathy (PMN), a rare kidney condition that can cause swelling in your lower body, tiredness, changes in urine, and weight gain. This research is studying ALXN1920, a potential new treatment, to see if it can help protect kidneys and prevent PMN from getting worse. Researchers want to find out how safe the study drug is, how well it works in your body, and if it can help reduce protein in your urine compared to a placebo (an inactive treatment).
Estimated Enrollment
30
Estimated End Date
17-Jun-26
Trial is for people with
Adults diagnosed with primary membranous nephropathy (PMN) who are at higher risk for kidney disease progression and are still losing ...
Study Goal
To learn if ALXN1920 can help preserve kidney function and prevent disease progression in people with PMN by lowering protein in the ...
What is involved for the patient?
If you join the study, you will continue your usual PMN treatment and also receive either ALXN1920 or placebo as a weekly infusion ...
About the drug or intervention
ALXN1920 is an investigational medicine designed to help regulate the immune system and protect the kidneys from damage caused by PMN. ...